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Elevated plasma brain natriuretic peptide levels in 
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M. BANDO, Y. ISHII, Y. SUGIYAMA AND S. KITAMURA 
Department of Pulmonary Medicine, Jichi Medical School, Tochigi, Japan 
Elevated plasma brain natriuretic peptide (BNP) levels have been described in patients with congestive heart failure 
and acute myocardial infarction. We measured plasma BNP levels in patients with chronic respiratory failure to 
evaluate the correlation between plasma BNP levels and pulmonary haemodynamics. Plasma BNP levels were 
measured in 28 patients with chronic respiratory failure accompanied by three underlying diseases [14 with chronic 
obstructive pulmonary disease (COPD), seven with sequelae of pulmonary tuberculosis (sequelae Tbc) and seven 
with diffuse panbronchiolitis (DPB)] by immunoradiometric assay methods (IRMA). Twenty-one of 28 patients had 
already received oxygen supplementation and 16 of 21 patients were treated as outpatients with home oxygen 
therapy. Plasma BNP levels were significantly elevated in patients with chronic respiratory failure complicated by 
car pulmonale (81.5 + 13.1 pg ml- ‘) compared to patients without car pulmonale (13.3 + 2.7 pg ml- ‘, P<O.OOl). 
As controls, plasma BNP levels in 10 patients with primary lung cancer were studied, and the results 
(3.5 i I.0 pg ml - ‘) were not significantly different from those of patients with chronic respiratory failure without 
car pulmonale. Plasma BNP levels in 12 healthy subjects were also studied, and the results (7.2 f 1.0 pg ml- ‘) were 
not significantly different from those of the control subjects. Plasma BNP levels showed a weak linear correlation 
with systolic pulmonary arterial blood pressure, estimated by Doppler echocardiography (~0.43; P=O.O68), but 
there was no significant correlation between BNP levels and the degree of hypoxaemia (~0.30; P=O.138). Plasma 
atria1 natriuretic peptide (ANP) levels in patients with chronic respiratory failure were also measured using the same 
samples. Plasma ANP levels were also significantly elevated in patients with chronic respiratory failure complicated 
by car pulmonale (80.8 i 12.1 pg ml- ‘) compared to patients without car pulmonale (26.1 f 4.4 pg ml- ‘, 
P=O.O03). A significant correlation was found between plasma BNP and ANP levels (r=0.68; P<O.OOl). Our results 
suggest that the plasma BNP or ANP level may be a useful indicator for detecting the presence of car pulmonale in 
patients with chronic respiratory failure. 
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Introduction 
Brain natriuretic peptide (BNP), a recent addition to the 
family of natriuretic peptides, has been isolated from 
porcine brain (l-3). In humans, a major source of circulat- 
ing BNP is cardiac tissue. BNP is produced in ventricular 
tissue, unlike atria1 natriuretic peptide (ANP), which is 
produced in the atrium. ANP has a role in regulating 
pulmonary vascular tone and may be involved in the 
pathophysiology of pulmonary hypertension (4,5). A recent 
study has suggested that the measurement of plasma ANP 
levels is useful for evaluating pulmonary hypertension (6). 
However, although elevated plasma BNP levels have been 
reported in patients with congestive heart failure (left 
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ventricular failure), acute myocardial infarction and in 
normal subjects after sodium loads (7-lo), the role of BNP 
in the pulmonary circulation is not fully understood. A 
recent study suggests that BNP blunts hypoxic pulmonary 
vasoconstriction in isolated perfused rat lung models (11). 
In humans, Cargill et al. (12) have shown that BNP 
blunts hypoxic pulmonary vasoconstruction in both healthy 
volunteers and in patients with car pulmonale. Studies have 
also shown elevated plasma BNP levels in patients with 
chronic obstructive pulmonary disease (13). Therefore, 
BNP may also play an important role in the patho- 
physiology of pulmonary hypertension and car pulmonale. 
Although some controversy still exists as to the precise 
definition of car pulmonale (14,15), car pulmonale is 
defined by the World Health Organization (WHO) as 
enlargement of the right ventricle (dilation and/or hyper- 
trophy) secondary to pulmonary hypertension from dis- 
eases of the lungs or pulmonary circulation (16). As right 
ventricular failure is not necessary for a diagnosis of car 
*~ll~~n~lp 2nd no snecific svm&oms are attributable to 
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TABLE 1. Characteristics of patients with chronic respiratory failure 
COPD 
(n= 14) 
Seq Tbc DPB 
(n= 7) (n=7) 
Age (years) 75.3 * 1.2 68.3 =k 2.2 64.4 zk 4.8 
Sex (M:F) 13:l 5:2 1:6 
VC (ml) 2194zt.35 145Ozt217 162Oxt27 
FEV, (ml) 1090 * 196 905Lk66 64Oiz27 
FEV,NC - ’ (%) 371k6 67xt 8 40% 3 
% FEV, 51.7 * 10.3 53.61t4.3 40.8 It 2.6 
P.40, (Torr) 74.2i 3.3 70.4* 5.5 66.0&4.4 
PACO, (Torr) 50.1 Zt 2.9 61.9 & 5.5 53.oIk4.3 
Patients with complicated car pulmonale (n) 6 4 3 
0, treatment 9 5 7 
COPD: chronic obstructive pulmonary disease; Seq Tbc: sequelae of pulmonary tuberculosis; DPB: 
diffuse panbronchiolitis; M: male; F: female; VC: vital capacity; FEV,: forced expiratory volume in 
1 set; % FEV,: predicted forced expiratory volume in 1 set; PAO,: arterial oxygen tension; PACO,: 
arterial carbon dioxide tension. 
diagnosis is based on physical signs, radiographical studies, 
electrocardiography, echocardiography, radionuclide 
studies and cardiac catheterization of only these (17,18). 
However, cardiac catheterization can document pulmonary 
hypertension unambiguously and hence can unequivocally 
admit a diagnosis of car pulmonale. 
In this study, we measured plasma BNP and plasma 
ANP concentrations in patients with chronic respiratory 
failure, some of whom did and some of whom did not have 
car pulmonale. Our goal was to determine whether the 
plasma BNP concentration correlated with the existence of 
car pulmonale. We also measured the BNP concentration 
longitudinally in individuals with car pulmonale to investi- 
gate whether changes in the BNP concentration correlated 
with changes in the clinical course. 
Methods 
PATIENTS 
Twenty-eight patients (nine women, 19 men; mean age 70.5 
years, range 42281 years) with chronic respiratory failure 
were investigated after informed consent. Underlying 
diseases included (Table 1): chronic obstructive pulmonary 
disease (COPD) in 14, sequelae of pulmonary tuberculosis 
(sequelae Tbc) in seven and diffuse panbronchiolitis (DPB) 
in seven. Twenty-one patients were treated with oxygen 
supplementation and 16 of these were treated as outpatients 
with home oxygen therapy at a mean flow rate of 
1.6 1 mini ’ for a mean of 50 months (range lo-120 
months). The remaining four patients were admitted as 
inpatients during periods of acute deterioration. Eighteen 
of the 28 patients were treated with diuretics, five patients 
were treated with digitalis and all patients were clinically 
stable according to physical and laboratory findings during 
the time of study except for the four patients who acutely 
deteriorated. Patients with systemic hypertension, renal 
diseases or ischaemic heart diseases were excluded. As 
control subjects, 10 inpatients with primary lung cancer 
(three women, seven men), who had not been treated, were 
studied. The mean age of control subjects was 69.2 years 
(range 62-76 years). They were clinically stable according 
to physical and laboratory findings [vital capacity (VC) 
2992 f 225 ml; forced expiratory volume in 1 set (FEV,) 
2010 f 270 ml]. We also measured plasma BNP levels in 12 
normal subjects (two women, 10 men; mean age 29.3 years, 
range 22-35 years). Patients were requested to rest quietly 
for at least 30 min before measurement and the arterial 
blood gas was drawn from the brachial artery. Spirometric 
tests were performed to evaluate respiratory function. 
Echocardiography was performed to assess systolic 
(ejection fraction) and diastolic (mitral inflow E/A ratio) 
function. Left-sided heart failure was defined according to 
the following criteria; ejection fraction less than 60% and 
E/A ratio less than 1 or over 2. Chronic respiratory failure, 
using the criteria of the Respiratory Failure Research 
Group in Japan, was defined as an arterial oxygen tension 
(PAOJ of less than 60 Torr on room air, for a period of at 
least 1 mcnth (19). A clinical diagnosis of car pulmonale 
was based on documentation of peripheral oedema with or 
without elevated jugulovenous pressure, a right ventricular 
heave on palpitation in the left parasternal area or 
increased intensity of the pulmonary component of the 
second heart sound on auscultation. In addition, diagnoses 
were made by chest roentgenograms which showed enlarge- 
ment of the pulmonary artery in the hilar regions, electro- 
cardiograms which showed right axis deviation and tall P 
waves (>2.5 mV) in standard lead II and echocardiograms 
which showed increased right ventricular dilatation and/or 
wall thickness in the subxiphoid approach in all cases. Cor 
pulmonale was present in 13 of 28 patients with chronic 
respiratory failure. As 19 patients had tricuspid regurgita- 
tion on Doppler echocardiography, we estimated right 
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ventricular systolic (pulmonary artery systolic) pressure 
(Pasp) using the following formula: Pasp=4 x V2+ Pra, 
where V is the maximum velocity of tricuspid regurgitant 
flow and Pra is the jugular venous pressure (20). Pulmonary 
hypertension was diagnosed using an estimated Pasp 
greater than 40 mmHg. 
MEASUREMENT OF PLASMA BNP AND ANP 
LEVELS 
Plasma samples were obtained from the brachial artery at 
the same time that the blood gas was drawn. They were 
immediately transferred to glass tubes containing 
Na,EDTA (1 mg ml - ‘) and aprotinin (1000 KIU ml - ‘), 
and centrifuged at 4°C. The plasma was immediately frozen 
and stored at - 80°C until the assay. Plasma BNP and 
ANP levels were determined using an immunoradiometric 
assay method (IRMA) (Shionoria ANP and BNP, Shionogi 
& Co, Ltd, Osaka, Japan) (21), which is available commer- 
cially (SRL Inc., Tokyo, Japan). In brief, a mixture of 
standard BNP (4-2000 pg 1 - i, 100 ~1) or sample (100 ~1) 
‘251-labelled monoclonal antibody (200~1) and a bead 
bearing another immobilized monoclonal antibody which 
recognizes the human BNP regions which maintain the 
integrity of both the C-terminal region and the disulphide 
bond-mediated ring structure, was incubated at 4°C for 
20 h. After removing the supernatant by aspiration, we 
washed the antibody bead twice with 2 ml of buffer. The 
radioactivity count in relation to the level of BNP calibra- 
tor was used to estimate the level of plasma BNP. In this 
assay, the minimum detectable quantity of human BNP was 
0.5 fmol ml- ‘. The degree of cross-reactivities with other 
natriuretic peptides were as follows: for the ANP assay, 
human ANP 100% and human BNP O.OOl%, and for the 
BNP assay, human BNP 100% and human ANP 0.001%. 
The intra-assay and interassay variations were less than 
10% in this assay system. 
DATA ANALYSIS 
Results are expressed as mean & SEM. Serum BNP and ANP 
levels in patients with chronic respiratory failure with 
or without car pulmonale, control subjects, and normal 
subjects were compared using the Mann-Whitney U-test. 
Linear regression analysis and statistics between plasma 
BNP and ANP levels and systolic pulmonary arterial blood 
pressure or blood gas analysis data (PAO,, PACO,) were 
performed using Stata Statistical Software 5.0 (Stata-Corp., 
College Station, TX, U.S.A.). Values of PcO.05 were 
considered to be statistically significant. 
Results 
The clinical data are summarized in Table 1. There was no 
significant intergroup difference in age or PAO, between 
controls, patients with car pulmonale and patients without 
car pulmonale. The male:female ratio was different in 
the DPB group compared with the other two groups. 
Twenty-six patients had their systolic pulmonary arterial 
blood pressure estimated by Doppler echocardiography; the 
systolic pulmonary arterial blood pressure could not 
be estimated in seven patients because of a tricuspid 
regurgitant jet. Thirteen patients (46.4%) were diagnosed 
with car pulmonale. Although the systolic pulmonary 
arterial blood pressure could be estimated in all patients 
with car pulmonale (57.6 i 4.3 mmHg), we could estimate 
the systolic pulmonary arterial blood pressure in only six of 
15 patients without car pulmonale (26.6 & 5.3 mmHg) 
(P=O,OO21). There was no correlation between plasma BNP 
levels and age. Plasma BNP and ANP levels in healthy 
subjects, control subjects, patients without car pulmonale 
and patients with car pulmonale are shown in Fig. 1. The 
mean BNP level in patients with chronic respiratory failure 
complicated by car pulmonale (81.5 & 13.1 pg ml- ‘) 
was significantly higher than in healthy subjects 
(7.2 It 1.0 pg ml- ‘), the control group (3.5 + 1.0 pg ml- ‘), 
or patients without car pulmonale (13.3 It 2.7 pg ml - ‘) 
(P<O.OOl). However, no differences were observed between 
the healthy group, the control group and patients without 
car pulmonale. The mean ANP level in patients with 
chronic respiratory failure complicated by car pulmonale 
(80.8 * 12.1 pg ml- ‘) was significantly higher than that in 
patients without car pulmonale (26~1 * 4.4 pg ml - ‘) 
(P=O.O03). Relationships between the plasma BNP levels 
and systolic pulmonary arterial blood pressure estimated by 
Doppler echocardiography and plasma ANP levels are 
shown in Fig. 2a and b. There was a weak correlation 
between plasma BNP levels and systolic pulmonary arterial 
blood pressure (u=O.43; P=O.O68). In addition, there was a 
significant correlation between plasma BNP levels and ANP 
levels (v=O.68; P<O,OOl), but not PaO, (~0.30; P=O.138) 
(Fig. 3). Relationships between the plasma ANP levels and 
systolic pulmonary arterial blood pressure estimated by 
Doppler echocardiography and PAO, are shown in Fig. 4(a) 
and (b). There was a weaker correlation between plasma 
ANP levels and systolic pulmonary arterial blood pressure 
(r=0.36; P=O.136), but not PAO, (v=O.l; P=O.627). Yasue 
et al. (22) showed that plasma BNP and ANP levels in 420 
healthy subjects were less than 20 pg ml - ’ (maximum 
18.4 pg ml - ‘, mean 5*9 pg ml - ‘) and less than 40 pg ml - i 
(maximum 27.5 pg ml - ‘, mean 11.3 pg ml - l), respectively, 
using the same methods. Our data also showed that the 
plasma BNP level was less than 20 pg ml - i in each healthy 
subject. Therefore, we set the normal BNP and ANP levels 
at less than 20 pg ml - i and less than 40 pg ml ~ li respect- 
ively. The sensitivity, specificity, positive predictive values 
and negative predictive values of plasma BNP and ANP are 
shown in Table 2. The sensitivity of BNP was higher than 
that of ANP, but its specificity was lower. We evaluated the 
regression of plasma BNP and ANP levels after treatment 
in four patients with acute exacerbations (Fig. 5). All 
four patients were treated with oxygen supplementation, 
diuretics and antibiotics. Subsequently, the mean PAO, and 
the mean systolic pulmonary arterial pressure improved 
from 53.5 Torr to 66.3 Torr, and from 62.5 mmHg to 
60.0 mmHg, respectively. Although plasma ANP levels did 
not decrease in three cases, plasma BNP levels decreased 
rapidly after treatment in all cases. 
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FIG. 2. Correlations of plasma BNP levels and systolic 
pulmonary arterial blood pressure (a) and plasma ANP 
levels (b). Linear correlations were found between plasma 
BNP concentrations and the systolic Ppa (7~0.43; 
P=O,O68) and plasma ANP levels (v=O.68; P<O.OOl). 
Ppa: pulmonary arterial blood pressure. 
Discussion 
In our study, plasma BNP concentrations were higher in 
patients with chronic respiratory failure complicated by car 
pulmonale than in healthy subjects, control subjects or 
patients without car pulmonale. In addition, a weak linear 
correlation was found between plasma BNP concentrations 
and systolic pulmonary arterial blood pressure estimated by 
Doppler echocardiography in patients with chronic respir- 
atory failure. Increased plasma BNP levels have been 
FIG. 1. Plasma BNP (a) and ANP (b) levels by IRMA in 
healthy subjects, controls, patients without car pulmonaie 
and patients with car pulmonale. Error bars are means. 
The BNP and ANP concentrations in the patients with 
car pulmonale were significantly higher when compared 
with the concentrations in healthy subjects or in patients 
without car pulmonale. 
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FIG. 3. Correlations of plasma BNP levels and PAO,. No 
linear correlations were found between the plasma BNP 
concentrations and PAO, (~0.30; P=O.138). 
reported in patients with predominantly left-sided heart 
failure (8,9). Hang et al. (23) demonstrated a weak linear 
correlation between plasma BNP levels and diastolic 
pulmonary arterial pressure or pulmonary capillary wedge 
pressure, a very close non-linear correlation with left 
ventricular end-diastolic pressure and a negative linear 
correlation with ejection fraction. However, the relation- 
ship between plasma BNP levels and pulmonary circulation 
has not been fully studied. Our data demonstrate that 
the plasma BNP level is a good indicator of pulmonary 
hypertension and car pulmonale. 
We found no significant differences between plasma BNP 
levels in patients with COPD, sequelae Tbc or DPB, which 
are the most common causes of chronic car pulmonale due 
to parenchymal lung diseases in Japan. Also, no differences 
were observed between the healthy group, control group 
and patients without car pulmonale. Our data suggest that 
plasma BNP levels may rise in cases of car pulmonale which 
result from various parenchymal lung diseases. Although 
car pulmonale is most often caused by parenchymal lung 
disease, problems with the ventilatory drive, the respiratory 
pumping mechanism or the pulmonary vascular bed may 
also result in right ventricular hypertrophy and dilatation. 
Prasad et al. (24) reported elevated plasma BNP levels in 
cases of pulmonary arterial hypertension secondary to 
recurrent thromboembolism. 
Because the clinical manifestations of car pulmonale are 
quite diverse, the diagnosis and assessment of patients is 
difficult. Patients with suspected pulmonary hypertension 
or car pulmonale may benefit from complete cardiac 
catheterization to confirm its presence and determine its 
severity. Because this technique is invasive, non-invasive 
tests such as electrocardiography, chest radiography and 
spirometric tests are sometimes used instead. Perreault et al. 
(6) have suggested that measurement of plasma ANP is 
useful for diagnosing pulmonary hypertension. The most 
sensitive non-invasive test for diagnosing pulmonary 
hypertension is echocardiography (25). Although these 
studies often are non-specific in evaluating pulmonary 
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FIG. 4. Correlations of plasma ANP levels and systolic 
pulmonary arterial blood pressure (a) and PAO, (b). No 
significant linear correlations were found between the 
plasma ANP concentrations and the systolic Ppa (r=0*36; 
P=O.136) and PAO, (r=O.l; P=O.627). Ppa: pulmonary 
arterial blood pressure. 
TABLE 2. Sensitivity, specificity, positive predictive value 
and negative predictive value of plasma BNP and ANP 
levels used to diagnose car pulmonale 
BNP ANP 
(%I (%I 
Sensitivity 100 69.2 
Specificity 73.3 86.7 
Positive PV 76.5 81.8 
Negative PV 100 76.5 
PV: predictive value. 
hypertension, and the value of any single test is limited, the 
use of two or more independent non-invasive tests increases 
diagnostic accuracy and reliability (18). In the present 
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Case Acute exacerbation After treatment 
PA& 1 41.3 (0, 0.5 1 min-l) 58.0 (OsO.75 1 mmr) 
(Torr) 2 64.1 (RA) 71.2 (PA) 
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4 51.8 (0, 11 min-l) 65.5 (0, 11 min-I) 
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(mmHg) 2 53 43 
3 72 66 
4 SO 71 
study, the specificity and sensitivity of the plasma BNI 
concentration for detecting car pulmonale were 73.3 am 
lOO%, respectively. Compared with the specificity am 
sensitivity of other non-invasive tests, including chest radio 
graphs (specificity 94%, sensitivity 36%), electrocardiogra 
phy (specificity 98%, sensitivity 57%) and echocardiography 
(specificity 94%, sensitivity 69%) as established in the WHC 
Multicenter Study (16), the plasma BNP concentration 
appears to be a more sensitive, although less specific, 
measure. However, specificity was improved by combining 
the plasma BNP and plasma ANP levels (specificity 100%, 
sensitivity 69.2%). Therefore, although it may be difficult to 
evaluate the presence of pulmonary hypertension using 
BNP levels alone, the measurement of both BNP and ANP 
may help to diagnose car pulmonale. 
A recent study has suggested that some differences exist 
between ANP and BNP secretion and metabolism (26). We 
also observed differences in the response of BNP and ANP 
levels in four cases of acute exacerbation. Jin et al. (27) 
suggested that endogenous ANP modulated the subacute, 
but not the acute, phase of hypoxic pulmonary hyperten- 
sion. Mukoyama et al. (8, 10) have shown that plasma BNP 
levels increase rapidly and markedly compared to ANP 
levels in congestive heart failure and within hours of the 
onset of an acute myocardial infarction. In addition, Lang 
et al. (13) have shown that plasma BNP levels are elevated 
in patients with acute exacerbations of COPD. Our data 
show that plasma BNP levels change rapidly after treat- 
ment. On the other hand, Cargill et al. (28) have shown that 
acute puhnonary vasoconstriction is associated with release 
of ANP but not BNP, and that there is a strong correlation 
between ANP release and the degree of hypoxic pulmonary 
vasoconstriction. These response patterns of plasma BNP 
and ANP suggest that they play complementary roles in the 
regulation of the pulmonary vascular response. Adachi 
et al. (29) have observed in rats that ANP mRNA levels in 
the right ventricle increase from day 3 to day 7 after 
pulmonary arterial banding and that BNP mRNA levels 
increase from day 1 through day 7 in right ventricular 
hypertrophy. Our data suggest that plasma BNP levels may 
be useful for following the course of individuals in whom 
car pulmonale has already occurred, especially during acute 
exacerbations. 
We found no correlation between the plasma BNP con- 
centrations and the degree of hypoxaemia. Although the 
mechanism responsible for BNP release is not yet under- 
stood, some studies have shown that the plasma BNP 
concentration increases with worsening hypoxaemia (13). 
These differences may occur because of the influence of 
oxygen supplementation. The PAO, data in our study were 
FIG. 5. Sequential changes in the plasma BNP (a) and 
ANP (b) concentrations in four patients with an acute 
exacerbation of chronic respiratory failure. (c) The 
plasma BNP concentrations decreased rapidly following 
successful treatment of the respiratory failure in all cases. 
The plasma ANP concentrations did not correlate with 
the clinical course. RA: on room air; Ppa: pulmonary 
arterial blood pressure. 
collected while patients were in a chronic steady-state 
with stable oxygen supplementation, except for the four 
patients experiencing an acute exacerbation. Thus it was 
difficult to determine the relationship between the plasma 
BNP concentration and the degree of hypoxaemia in this 
study. 
In conclusion, although measuring the central haemo- 
dynamics invasively would have improved the authority of 
this study, current data strongly suggest that an elevation in 
the plasma BNP concentration correlates with presence of 
car pulmonale. A larger study, testing whether the plasma 
BNP concentration is able to discriminate between patients 
with respiratory failure who do and do not have car 
pulmonale, is needed. Longitudinal studies in patients with 
car pulmonale correlating changes in the BNP concen- 
tration with the clinical course of the disease also are 
required. 
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